Dr. Jonathan Plehn is Vice President of Cardiovascular Medicine at Covance, Inc., a large contract research organization (CRO) and a division of the Laboratory Corporation of America. After a 25 year career in academic cardiology, Dr. Plehn left the National Heart, Lung and Blood Institute and the National Naval Medical Center in 2008 to start up the Cardiovascular-Metabolic therapeutic area at Covance. His research and clinical interests have included epidemiology (Framingham Heart Study), heart failure, vascular disease and advanced cardiac imaging. He has participated in numerous cardiovascular trials both on the investigator and industry sides and has a special interest in cardiovascular outcomes trials and adjudication methodologies. At Covance his group provides medical/scientific oversight in phase 1b-4 trials ranging from novel pharmacologic and biologic approaches to lipid disorders to regenerative medicine in heart failure and genetic and enzyme-based treatments of rare cardiomyopathies. He is the author of more than 140 publications, sits on the editorial board of the Journal of Cardiac Failure and is a Clinical Professor of Medicine at the Drexel School of Medicine.